CD44 as a prognostic and predictive marker for GBM.


2049 Background: While GBM has a poor prognosis overall, molecular subsets of tumors exist with differential outcome to initial treatment. Finding biomarkers of outcome would be beneficial prognostically and help understand resistance mechanisms. Previous GBM molecular subtyping demonstrated that the mesenchymal GBM subtype has worse prognosis compared to… (More)


Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.

Slides referencing similar topics